Under construction – not a live service
Sign in
Taking people in JapanNo phase

Sleep habits and muscle loss in lung disease patients

Studies how sleep habits relate to muscle loss and thinking problems in COPD or IPF.

Plain-language title generated from the registry record
Registry title: Sleep Hygiene, Sarcopenia, and Cognitive Function in Respiratory Disease

Key facts

Where
Jōyō, JapanSee the site

Where in Japan

  • National Hospital Organization Minami Kyoto HospitalJōyō, JapanTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
National Hospital Organization Minami Kyoto Hospital
Trial code
NCT05193136
Record updated
28 March 2023
Original description
We aim to clarify the relationship between sleep hygiene and the onset of sarcopenia or cognitive dysfunction using sleep time, arousal, and sleep quality as indicators in COPD or IPF patients, and clarify the effects of sleep hygiene on disease progression and life prognosis.Read full original descriptionShow less

Examination of the Relationship Between Sleep Hygiene, Sarcopenia, and Cognitive Function in Patients With Chronic Obstructive Pulmonary Disease or Idiopathic Pulmonary Fibrosis

We aim to clarify the relationship between sleep hygiene and the onset of sarcopenia or cognitive dysfunction using sleep time, arousal, and sleep quality as indicators in COPD or IPF patients, and clarify the effects of sleep hygiene on disease progression and life prognosis.

Inclusion: Subjects with COPD or IPF.

Exclusion: Subjects receiving long-term oxygen therapy (LTOT) or non-invasive ventilation therapy (NIV); Subjects who have been hospitalized for exacerbation of respiratory failure within 1 month of study participation; Subjects with severe complications such as cardiovascular disease, liver disease, renal disease, malignancy, and neurological disease; Subjects who have already been diagnosed with sarcopenia or cognitive dysfunction; Subjects with obstructive sleep apnea who are indicated for continuous positive airway pressure (CPAP).

ClinicalTrials.gov NCT05193136